LONDON: Lung cancer patients in England will become the first in Europe to receive a drug made by US biotech firm Amgen that targets a specific gene mutation, the country's health service said on Friday .
The drug, taken as a tablet, will be used on patients with the KRAS G12C mutation that occurs in about 13 per cent of non-small cell lung cancers , the most common type of lung cancer. "This revolutionary treatment has taken decades of research to reach the clinic, and now that it is here this new targeted drug will be available for eligible people with lung cancer as quickly as possible thanks to this agreement," said Peter Johnson, NHS clinical director for cancer.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: